Anticoagulation therapy is a mainstay of the treatment
of thrombotic
disorders; however, conventional anticoagulants trade antithrombotic
benefits for bleeding risk. Factor (f) XI deficiency, known as hemophilia
C, rarely causes spontaneous bleeding, suggesting that fXI plays a
limited role in hemostasis. In contrast, individuals with congenital
fXI deficiency display a reduced incidence of ischemic stroke and
venous thromboembolism, indicating that fXI plays a role in thrombosis.
For these reasons, there is intense interest in pursuing fXI/factor
XIa (fXIa) as targets for achieving antithrombotic benefit with reduced
bleeding risk. To obtain selective inhibitors of fXIa, we employed
libraries of natural and unnatural amino acids to profile fXIa substrate
preferences. We developed chemical tools for investigating fXIa activity,
such as substrates, inhibitors, and activity-based probes (ABPs).
Finally, we demonstrated that our ABP selectively labels fXIa in the
human plasma, making this tool suitable for further studies on the
role of fXIa in biological samples.